Labeling symbols are a routine element of medical device packaging, yet they sit at the intersection of international standards, national regulatory requirements, and submission-specific review criteria. For regulatory affairs and quality professionals, a symbol that appears technically correct can still generate a deficiency if the underlying standard version, adjacent text policy, or glossary disclosure requirement is not aligned with the applicable framework.
This analysis examines how FDA, EU MDR, and Health Canada each incorporate or reference ISO 15223-1, the conditions under which stand-alone symbols are permitted, and where symbol and labeling deficiencies have recurred in FDA 510(k) reviews, warning letters, and Form 483 observations.
Want Rhizome's help on your own question? Try it for free.
Symbols on medical device labels and IFU: how FDA, EU MDR, and Health Canada treat ISO 15223-1, and where labeling deficiencies surface in FDA reviews and enforcement
Symbols carry a lot of regulatory weight for a graphic that occupies a few millimeters of a label. They replace multilingual text, encode manufacturer identity and handling conditions, and signal MR compatibility, sterility, and single use. All three major North American and European frameworks now lean on the same international standard, ISO 15223-1, but they reach it by different legal routes and impose different conditions. The gap between "the symbol is on the label" and "the symbol is compliant" is exactly where reviewers, inspectors, and warning-letter authors keep finding problems.
United States: 21 CFR 801.15, the 2016 symbols rule, and ISO 15223-1 recognition
The baseline US requirement is 21 CFR 801.15, which governs how mandatory labeling information must be displayed and requires that it appear in a manner "obvious to the reader" 200. Device labeling must satisfy the applicable requirements of 21 CFR Part 801 as a whole 196200.
Historically, FDA required a symbol to be accompanied by adjacent explanatory text unless the symbol was established in a rule. That changed with the 2016 final rule, "Use of Symbols in Labeling," which amended 21 CFR 801.15 186196. The practical effect familiar to regulatory affairs teams is that a manufacturer may use a stand-alone symbol without adjacent explanatory text when the symbol is contained in a standard developed by a standards development organization, is used in accordance with that standard, and the labeling includes a paper or electronic symbols glossary. ISO 15223-1 (Medical devices — Symbols to be used with information to be supplied by the manufacturer) is the standard most commonly relied on for this purpose, and FDA recognizes it as a consensus standard.
In practice, FDA-cleared devices routinely document ISO 15223-1 conformance in their submissions. The CARESCAPE Respiratory Modules clearance (K211317) states that the device "conforms with the following FDA-recognized standards ... ISO 15223-1 Medical devices - Symbols to be used with medical device labels, labeling, and information to be supplied - Part 1: General requirements" 151. Wound-therapy devices RENASYS EZ MAX (K143133) and RENASYS EZ PLUS (K151326) both list ISO 15223-1:2012 together with ISO 15223-2:2010, the companion standard for symbol development, selection, and validation 153166. The thermometer clearance ThermoTK (K213256) cites the 2016 edition of ISO 15223-1 155. These examples show the expected submission pattern: name the recognized standard, confirm the symbols are used per that standard, and provide the glossary.
A note on document scope for readers who want to go deeper: the older FDA labeling references still in circulation include "Labeling - Regulatory Requirements for Medical Devices" (FDA 89-4203, 1989) 186 and, for MR symbols specifically, "Testing and Labeling Medical Devices for Safety in the Magnetic Resonance (MR) Environment" (2023) 196. The MR guidance is the reason MR Conditional and MR Safe symbols appear so often in labeling-change 510(k)s, discussed below.
European Union: MDR Annex I Section 23 and the EN ISO 15223-1 pathway
Under Regulation (EU) 2017/745 (MDR), the labeling and instructions-for-use requirements live in Annex I, Chapter III, Section 23. Section 23 requires that each device be accompanied by the information needed to identify the device and its manufacturer, plus the safety and performance information relevant to the user; that information may appear on the device, on the packaging, or in the IFU, and must also be kept current on the manufacturer's website if one exists 115. Section 23.1 sets the overarching principle that the label and IFU must be appropriate to the device, its intended purpose, and the knowledge and training of the intended users, written in terms readily understood by the intended user and, where appropriate, supplemented with drawings and diagrams 1.
The symbols provision is Section 23.1(h): where appropriate, the information supplied by the manufacturer shall take the form of internationally recognised symbols, and any symbol or identification colour used shall conform to the harmonised standards or common specifications (CS); where no harmonised standard or CS exists, the symbols and colours must be described in the documentation supplied with the device 1. This is a stronger obligation than the US position. Symbols are not merely permitted subject to a glossary; when used, they must conform to the harmonised standard.
The harmonised standard for that purpose is EN ISO 15223-1:2021, identified in MDCG 2021-5 Rev. 1 (Guidance on standardisation for medical devices), which ties symbol use back to MDR Annex I Section 23.1(h) and carries an Official Journal citation supporting MDR/IVDR conformity 7027. Two operational points from the MDCG material matter for current labeling projects:
- The EU REP transition. An appendix to MDCG 2021-5 Rev. 1 addresses the change of the authorised-representative symbol from "EC REP" to "EU REP" in EN ISO 15223-1. Compliance is supported by EN ISO 15223-1:2021 together with amendment A1:2025, and there is a coexistence period until 17 June 2031, after which conformity is granted only by using the 2021 standard with A1:2025 (that is, the EU REP symbol) 731345. Manufacturers should plan artwork updates around that 2031 cutoff rather than treating the change as optional.
- Class I and national language. MDCG 2019-15 rev. 1 (guidance for manufacturers of Class I devices) confirms that national language requirements apply and that labelling and IFU in the relevant national languages should sit in the technical documentation, and it restates the internationally-recognised-symbols expectation 74.
More recently, MDCG 2025-4 on making medical device software (MDSW) apps available on online platforms extends labelling and marking expectations into the digital storefront: platforms should display the device name, manufacturer details, the MD/IVD symbol, warnings, and a link to the electronic IFU 76. This is a useful signal that MDR symbol and eIFU obligations are being read to follow the product to wherever it is presented to the user.
Health Canada: directions-for-use focus, bilingual labelling, and a less explicit symbol regime
Health Canada's labelling expectations, as reflected in its guidance corpus, center on adequate directions for all intended uses rather than on a symbols framework. For disinfectant and sterilant products used with reusable medical devices, the label must carry adequate directions for all intended uses, including device categories, pre-cleaning, activator use, contact time and cycle conditions, terminal rinse steps, compatibility limits, warnings, hazard statements, and storage as applicable 128116118120130. Hard-surface disinfectant guidance similarly requires intended use areas, dilutions, and application method 137138.
On language, Health Canada's plain-language labelling regime for prescription drugs requires bilingual (English and French) label mock-ups at filing and finalized versions in both official languages before approval, and recommends a minimum 9-point sans-serif font 17. For foreign-authorized products, Health Canada may accept labelling provided in either English or French 127126. The current "Labelling of pharmaceutical drugs for human use" guidance (updated December 2024) sets out the drug-side expectations 119123134.
An important scoping caveat for readers: the Health Canada guidance retrieved here does not explicitly confirm recognition of ISO 15223-1 for device symbols. The only symbol-specific content is an archived labelling standard for ethylene oxide sterilization products, which requires a hazard symbol and warning statement and points to the Food and Drug Regulations for hazard symbols, not to ISO 15223-1 18. This is a genuine gap in the retrieved material rather than a finding that Health Canada rejects the standard; a reader assessing a Canadian device licence application should confirm the current Medical Devices Regulations labelling provisions and Health Canada's recognized-standards list directly, and can ask Rhizome to pull those specific sources.
Where symbol and labeling deficiencies actually appear in FDA files
510(k) reviews: mismatches, glossaries, and standard conformance
Symbol and labeling issues in 510(k) files fall into a few recurring patterns. The most consequential is a mismatch between the device's tested performance and its labeling/IFU. In the NeoCoil 3.0T carotid array coil review (K070778), the reviewer flagged a discrepancy between device performance and the "labeling, IFU and 510(k) summary," which the sponsor corrected only after FDA requested additional information 98. For the Prosigna breast-cancer prognostic assay (K141771), FDA required that "all labeling and software must indicate" the FLEX configuration is acceptable for IVD use only in IVD mode, tying a labeling statement directly to the cleared claim 99. In the Sensor Touch temporal thermometer review (K011291), FDA requested the historical file of labels, labeling, and promotional material to confirm labeling modifications 8587.
The affirmative, well-executed pattern is equally instructive because it shows what reviewers expect to see. Sponsors present a symbols legend and confirm standard conformance: the intense pulsed light device (K232708) includes a dedicated "Symbol Description" chapter listing Manufacturer, Manufacturing Date, Serial Number, general warning signs, Type BF applied part, and a laser-output warning 147. Orthopedic sponsors updating legacy portfolios describe adopting "new internationally recognized symbols with corresponding updated symbols glossaries," as in the Pinnacle constrained acetabular liners (K240639) and the DePuy Summit hip prosthesis (K231873) 152156. MR labeling supplements are a common vehicle for symbol additions: the Biolox delta ceramic heads submission (K200959) added MR Conditional language to the IFU and the MR Conditional symbol to the package label 157, and MicroPort's total hip systems (K173898) updated package inserts and package labels to include MR Conditional language and symbols 170. A standards-version change can itself drive a labeling update, as when the Verify chemical indicator (K172746) moved its indicator reference from "Class 1" to "Type 1" per ANSI/AAMI/ISO 11140-1:2014 798495. FDA decision letters also reiterate the general baseline that "device labeling must be truthful and not misleading" (K230517) 164.
Warning letters: misbranding and inadequate directions for use
On the enforcement side, the dominant device-labeling theme in warning letters is misbranding for failure to bear adequate directions for use. FDA cited this against Medical Supply Liquidators for prescription devices whose labeling failed to bear adequate directions for use 46, against Sepal Reproductive Devices for devices that did not bear adequate directions and did not meet exemption requirements 48, and against Kids Company for the Pyro-Energen II device, where adequate directions could not be written for the claimed treatment of diseases such as cancer 62. The Cotton High Tech (COHITECH) letter is the most labeling-systematic: FDA cited tampons as misbranded for failing to provide adequate directions for use, faulted a labeling control procedure that did not ensure Toxic Shock Syndrome information appeared on cartons and labels, and found the package insert deficient against the menstrual-tampon user-labeling requirements of 21 CFR 801.430 55. Related letters reach missing required warnings and repackaging without adequate package inserts (Direct Dispensing) 61 and a missing place-of-business address under 21 CFR 201.1 (PoppySeed Wash) 63.
Form 483 observations: labeling controls and label reconciliation
Form 483 observations concentrate on labeling-control systems rather than on symbol content per se. The clearest device example is Dexcowin, where a complaint alleged that portable x-ray devices "may be incorrectly labeled" because a removable label sat over the permanently affixed model label and the removable focal-spot sticker obscured the skin-source distance indication 30. Legacy Pharmaceutical Packaging drew observations that its vision system detected labeling nonconformances during qualification runs but the rejections were never recorded, and that the OCR system was never challenged with an incorrect carton part code or incorrect UDI barcode 1922, a direct labeling-and-UDI control gap. The remaining high-frequency observations are label reconciliation and issuance-control failures: Central Admixture Pharmacy Services released products without reconciling labels after the labeling operation 20; Neeyaan lacked access control over label storage and packaging/label reconciliation 21; Edge Pharmacy did not document disposition of rejected labeling, perform container-label reconciliation, or set label rejection acceptance limits, and omitted required outsourcing-facility label content under section 503B(a)(10)(A) 23; California Pharmacy's labeling SOP failed to address label issuance, identification, storage, handling, sampling, and reconciliation, and omitted the required "This is a compounded drug," "Not for resale," and "Office Use Only" statements 24; and Biocon did not verify or reconcile API status labels before affixing them 29. Many of these facilities are drug and compounding operations governed by Part 211 labeling controls rather than device labeling controls under 21 CFR 820.120 and 820.130, so treat them as illustrations of how FDA scrutinizes labeling issuance, reconciliation, and control generally; the Dexcowin and Legacy examples are the most directly device-relevant.
What this means in practice
The three frameworks converge on ISO 15223-1 as the reference standard but diverge on how binding it is. In the EU, MDR Annex I Section 23.1(h) makes conformance of any symbol used mandatory, with EN ISO 15223-1:2021 (plus A1:2025 and the EU REP transition to 2031) as the harmonised route 1734. In the US, ISO 15223-1 is the recognized standard that unlocks stand-alone symbol use under the 2016 amendment to 21 CFR 801.15, conditioned on a symbols glossary 186200. Health Canada's retrieved guidance emphasizes adequate directions for use and bilingual labelling and does not, in the material reviewed here, explicitly adopt ISO 15223-1, so that point warrants direct confirmation 1718128. The enforcement record shows the recurring failure modes are not exotic: labeling that does not match tested performance or cleared claims in 510(k)s 9899, misbranding for inadequate directions for use in warning letters 464855, and weak label issuance and reconciliation controls in Form 483s 202330. A symbols glossary that matches the artwork, a documented standard-conformance statement, and label-control procedures that actually reconcile what was printed remain the low-cost defenses against the most common findings.